Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

BACKGROUND: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Hoffmann, Katrin, Ganten, Tom, Gotthardtp, Daniel, Radeleff, Boris, Settmacher, Utz, Kollmar, Otto, Nadalin, Silvio, Karapanagiotou-Schenkel, Irini, von Kalle, Christof, Jäger, Dirk, Büchler, Markus W, Schemmer, Peter
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4449604/
https://ncbi.nlm.nih.gov/pubmed/25957784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1373-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы